ABOUT PHARMAIN

Founded in 2000, PharmaIN Corp. is a developer of proprietary peptide-based therapeutics to address critical unmet medical needs. We focus on advancing two new drug candidates:

PHIN-214

Target Indication:
Treatment of refractory ascites due to advanced liver cirrhosis
Status:
A US Phase 1b clinical trial is underway in compensated or decompensated cirrhotic patients at multiple clinical trial centers

PHIN-214 is an investigational drug therapy that has not been approved by the FDA or any other regulatory agency around the world.

PHIN-1314

Target Indication:
Immuno-oncology treatment for solid tumors
Status:
Aiming to enter GLP tox in 2023

MANAGEMENT TEAM

Elijah Bolotin, PhD
Founder, President and CEO

Elijah has over 20 years of experience in biopharma science and business, including leading technical roles in Joint Ventures of Endorex Corp with Elan and Novo Nordisk, as well as research at NYU Medical Center. He is inventor and co-inventor of numerous patents, and received his PhD from The Hebrew University, Israel, in biochemistry and pharmaceuticals.

Gerardo Castillo, PhD
VP, Technology & Intellectual Property

Gerry has over 20 years of experience in clinical and analytical biochemistry, drug development, drug delivery, patent drafting and prosecution, and author of numerous manuscripts and presentations. Prior to PharmaIN, Gerry was a Director of Biochemistry and a Drug Discovery Leader at ProteoTech Inc. Gerry received his PhD in Clinical Biochemistry from the University of Toronto, MS in Clinical Chemistry from University of Windsor, BS in Biochemistry from University of Saskatchewan, certified in Regulatory Affairs, a Registered Patent Agent, and an inventor with over 100 patents under his name.

Joshua Alfaro, PhD
Director, CMC and Bioanalytical

Joshua has over 10 years industry experience in chemistry ranging from organic synthesis to methods development for the analysis of protein post-translation modifications and copolymers. Prior to PharmaIN, he worked as a postdoctoral researcher at WSU and Pacific Northwest National Laboratory, and as a scientist in the biotech/pharma industry. He received his Phd in Organic Chemistry from Washington State University.

Cynthia Jones
Manager, Clinical Operations & Quality Assurance

Cyndy has over 20 years of experience in pharmaceutical manufacturing and process development. Prior to PharmaIN, she was a chemist at DuPont de Nemours focused on protein purification and at Baxter supporting vaccine manufacturing. Cyndy received a BS in Chemistry from the University of New Hampshire.

Shraddha Bhargava, MBA
Manager, Finance and Operations

Shraddha has over 20 years of experience as a Manager of Finance and Operations in diverse domains including 5+ years in the BioPharma industry. Prior to PharmaIN, Shraddha had managed several commercial operations as well as started her own business. Shraddha received a BS in Business Administration from Carnegie Mellon University and an MBA from Duquesne University.

Akiko Nishimoto-Ashfield
Associate Director, Business Development

Akiko has over 15 years of experience in biochemistry and R&D. Prior to PharmaIN, she was a chemist at Lumera/Plexera Bioscience focused on protein microarray and surface plasmon resonance, as well as polymer and proprietary chromophore characterization. Akiko received a BS in Biochemistry from Seattle Pacific University.

Strategic/Investment Partnerships

PharmaIN has established strategic/investment partnerships with three leading global pharmaceutical companies:

PHARMAIN_web_Shionogi_logo_stack

May 21st, 2017 __ Asahi Kasei Corporation invests in PharmaIN

Bothell, WA & Osaka, Japan – (January 4th, 2018) – PharmaIN Corporation and Shionogi & Co., LTD announced today that they entered into a Collaboration Agreement with an exclusive two-year Option to negotiate a License for the collaboration product. Shionogi Corp. will make an equity investment of up to $17M USD in PharmaIN in three tranches. [read more here]

Bothell, WA & Kanagawa, Japan – (June 5th, 2019) – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today a strategic partnership with Seattle-based PharmaIN Corporation (“PharmaIN”) for the purpose of investigating the use of PharmaIN’s proprietary drug carrier and delivery Protected Graft Co-Polymer (“PGC™”) technology in combination with PeptiDream’s peptide discovery and development programs. [read more here]

Strategic/Investment Partnerships

PharmaIN has established strategic/investment partnerships with three leading global pharmaceutical companies:

May 21st, 2017 __ Asahi Kasei Corporation invests in PharmaIN

Bothell, WA & Osaka, Japan – (January 4th, 2018) – PharmaIN Corporation and Shionogi & Co., LTD announced today that they entered into a Collaboration Agreement with an exclusive two-year Option to negotiate a License for the collaboration product. Shionogi Corp. will make an equity investment of up to $17M USD in PharmaIN in three tranches. [read more here]

Bothell, WA & Kanagawa, Japan – (June 5th, 2019) – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today a strategic partnership with Seattle-based PharmaIN Corporation (“PharmaIN”) for the purpose of investigating the use of PharmaIN’s proprietary drug carrier and delivery Protected Graft Co-Polymer (“PGC™”) technology in combination with PeptiDream’s peptide discovery and development programs. [read more here]